Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.


Journal Article

OBJECTIVE: The authors examined whether initial assignment to receive placebo for 12 weeks followed by open active treatment as clinically indicated was associated with different levels of benefit and risk of harm across 36 weeks as compared with initial assignment to receive active treatments. METHOD: Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo. Assessments were conducted every 6 weeks for 36 weeks. The primary outcome measures were response and remission based on scores on the Children's Depression Rating Scale-Revised and the Clinical Global Impression improvement subscale. RESULTS: At week 36, the response rate was 82% in the placebo/open group and 83% in the active treatment groups. The remission rate was 48% in the placebo/open group and 59% in the active treatment groups, a difference that approached statistical significance. Patients who responded to placebo generally retained their response. Those who did not respond to placebo subsequently responded to active treatment at the same rate as those initially assigned to active treatments. There were no differences between groups in rates of suicidal events, study retention, or symptom worsening. CONCLUSIONS: Remission rates at 9 months were lower in patients treated initially with placebo, but 3 months of placebo treatment was not associated with any harm or diminished response to subsequent treatment.

Full Text

Duke Authors

Cited Authors

  • Kennard, BD; Silva, SG; Mayes, TL; Rohde, P; Hughes, JL; Vitiello, B; Kratochvil, CJ; Curry, JF; Emslie, GJ; Reinecke, MA; March, JS; TADS,

Published Date

  • March 2009

Published In

Volume / Issue

  • 166 / 3

Start / End Page

  • 337 - 344

PubMed ID

  • 19147693

Pubmed Central ID

  • 19147693

Electronic International Standard Serial Number (EISSN)

  • 1535-7228

Digital Object Identifier (DOI)

  • 10.1176/appi.ajp.2008.08040487


  • eng

Conference Location

  • United States